Bridge City Capital’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.25M | Sell |
62,923
-878
| -1% | -$44.7K | 0.9% | 36 |
|
|
2025
Q4 | $3.17M | Sell |
63,801
-9,015
| -12% | -$438K | 0.93% | 42 |
|
|
2025
Q3 | $3.48M | Sell |
72,816
-19,917
| -21% | -$802K | 0.93% | 44 |
|
|
2025
Q2 | $2.92M | Sell |
92,733
-1,447
| -2% | -$46.4K | 0.82% | 53 |
|
|
2025
Q1 | $3.08M | Sell |
94,180
-817
| -0.9% | -$28.9K | 0.93% | 47 |
|
|
2024
Q4 | $3.44M | Buy |
94,997
+761
| +0.8% | +$26.8K | 0.92% | 43 |
|
|
2024
Q3 | $2.94M | Buy |
94,236
+11,951
| +15% | +$373K | 0.81% | 54 |
|
|
2024
Q2 | $2.2M | Buy |
82,285
+1,625
| +2% | +$47.1K | 0.74% | 60 |
|
|
2024
Q1 | $2.75M | Buy |
80,660
+1,985
| +3% | +$59.1K | 1% | 45 |
|
|
2023
Q4 | $2.28M | Buy |
78,675
+13,378
| +20% | +$355K | 0.88% | 57 |
|
|
2023
Q3 | $1.8M | Buy |
65,297
+2,469
| +4% | +$75.2K | 0.91% | 56 |
|
|
2023
Q2 | $1.89M | Buy |
62,828
+38
| +0.1% | +$1.33K | 0.89% | 53 |
|
|
2023
Q1 | $2.27M | Sell |
62,790
-230
| -0.4% | -$8.84K | 1.14% | 35 |
|
|
2022
Q4 | $2.25M | Sell |
63,020
-448
| -0.7% | -$15.6K | 1.15% | 32 |
|
|
2022
Q3 | $2.15M | Buy |
63,468
+2,116
| +3% | +$68.9K | 1.18% | 30 |
|
|
2022
Q2 | $1.77M | Sell |
61,352
-109
| -0.2% | -$3.12K | 0.94% | 50 |
|
|
2022
Q1 | $1.99M | Sell |
61,461
-47,401
| -44% | -$1.45M | 0.93% | 51 |
|
|
2021
Q4 | $3.17M | Sell |
108,862
-22
| -0% | -$667 | 1.31% | 23 |
|
|
2021
Q3 | $2.9M | Sell |
108,884
-28,898
| -21% | -$776K | 1.32% | 27 |
|
|
2021
Q2 | $4.24M | Sell |
137,782
-4,581
| -3% | -$140K | 1.45% | 23 |
|
|
2021
Q1 | $3.73M | Sell |
142,363
-1,450
| -1% | -$40.6K | 1.24% | 34 |
|
|
2020
Q4 | $3.62M | Sell |
143,813
-1,496
| -1% | -$32.2K | 1.37% | 27 |
|
|
2020
Q3 | $3.03M | Buy |
145,309
+21,535
| +17% | +$489K | 1.45% | 22 |
|
|
2020
Q2 | $2.94M | Buy |
123,774
+1,291
| +1% | +$28.5K | 1.35% | 25 |
|
|
2020
Q1 | $2.2M | Buy |
122,483
+14,285
| +13% | +$300K | 1.07% | 40 |
|
|
2019
Q4 | $2.57M | Buy |
108,198
+20,072
| +23% | +$487K | 1.06% | 39 |
|
|
2019
Q3 | $2.42M | Buy |
88,126
+19,126
| +28% | +$567K | 1.04% | 43 |
|
|
2019
Q2 | $2.28M | Buy |
69,000
+338
| +0.5% | +$11.6K | 1.26% | 27 |
|
|
2019
Q1 | $2.41M | Buy |
68,662
+17,256
| +34% | +$642K | 1.4% | 22 |
|
|
2018
Q4 | $1.71M | Buy |
51,406
+5,563
| +12% | +$239K | 1.11% | 40 |
|
|
2018
Q3 | $2.31M | Sell |
45,843
-1,952
| -4% | -$96.4K | 1.43% | 20 |
|
|
2018
Q2 | $2.86M | Sell |
47,795
-1,595
| -3% | -$82.6K | 1.81% | 5 |
|
|
2018
Q1 | $2.26M | Buy |
49,390
+2,995
| +6% | +$125K | 1.52% | 16 |
|
|
2017
Q4 | $1.85M | Hold |
46,395
| – | – | 1.34% | 24 |
|
|
2017
Q3 | $1.86M | Buy |
46,395
+3,740
| +9% | +$162K | 1.39% | 21 |
|
|
2017
Q2 | $1.84M | Buy |
+42,655
| New | +$1.52M | 1.53% | 18 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Bridge City Capital's SUPN Position: Q1 2026 in Review
Bridge City Capital reduced its Supernus Pharmaceuticals (SUPN) stake by 1.4% in Q1 2026, selling an estimated $44.7K and leaving 62,923 shares worth $3.25M. The position accounts for 0.9% of the portfolio, ranked #36.
Bridge City Capital first reported a position in SUPN in Q2 2017 and has held it in 36 quarters since. The position peaked at $4.24M in Q2 2021. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Bridge City Capital held 62,923 shares of Supernus Pharmaceuticals worth $3.25M as of Q1 2026.
- Bridge City Capital sold 878 Supernus Pharmaceuticals shares in Q1 2026, an estimated $44.7K.
- Supernus Pharmaceuticals made up 0.9% of Bridge City Capital's portfolio in Q1 2026, its #36 holding.
- Bridge City Capital first reported a position in Supernus Pharmaceuticals in Q2 2017 and has held it in 36 quarters since.
- Bridge City Capital's Supernus Pharmaceuticals position peaked at $4.24M in Q2 2021.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Bridge City Capital's 13F filing for Q1 2026, filed 13 May 2026.